333 related articles for article (PubMed ID: 35740580)
1. Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.
Sheikh IN; Elgehiny A; Ragoonanan D; Mahadeo KM; Nieto Y; Khazal S
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740580
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma.
Harker-Murray PD; Pommert L; Barth MJ
J Natl Compr Canc Netw; 2020 Aug; 18(8):1125-1134. PubMed ID: 32755987
[TBL] [Abstract][Full Text] [Related]
4. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Osumi T; Mori T; Fujita N; Saito AM; Nakazawa A; Tsurusawa M; Kobayashi R
Pediatr Blood Cancer; 2016 Oct; 63(10):1794-9. PubMed ID: 27314926
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
6. CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm.
Hill L; Lulla P; Heslop HE
Adv Cell Gene Ther; 2019 Jul; 2(3):. PubMed ID: 31777773
[TBL] [Abstract][Full Text] [Related]
7. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
8. Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Yin Z; Zhang Y; Wang X
Biomark Res; 2021 Jul; 9(1):58. PubMed ID: 34256851
[TBL] [Abstract][Full Text] [Related]
9. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
10. Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas.
Poggio T; Duyster J; Illert AL
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30231561
[TBL] [Abstract][Full Text] [Related]
11. CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.
Ostojska M; Nowak E; Twardowska J; Lejman M; Zawitkowska J
J Pers Med; 2023 Nov; 13(11):. PubMed ID: 38003910
[TBL] [Abstract][Full Text] [Related]
12. Non-Hodgkin lymphoma in Jordan. Types and patterns of 111 cases classified according to the WHO classification of hematological malignancies.
Almasri NM; Habashneh MA; Khalidi HS
Saudi Med J; 2004 May; 25(5):609-14. PubMed ID: 15138528
[TBL] [Abstract][Full Text] [Related]
13. Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
Kanwal B
Cureus; 2021 Jul; 13(7):e16307. PubMed ID: 34277304
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.
Itzhaki O; Jacoby E; Nissani A; Levi M; Nagler A; Kubi A; Brezinger K; Brayer H; Zeltzer LA; Rozenbaum M; Vernitsky H; Markel G; Toren A; Avigdor A; Schachter J; Besser MJ
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152221
[TBL] [Abstract][Full Text] [Related]
15. State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY.
Heerema NA; Bernheim A; Lim MS; Look AT; Pasqualucci L; Raetz E; Sanger WG; Cairo MS
Pediatr Blood Cancer; 2005 Oct; 45(5):616-22. PubMed ID: 16127683
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
[TBL] [Abstract][Full Text] [Related]
17. Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy.
Li Y; Liu Y; Yang K; Jin L; Yang J; Huang S; Liu Y; Hu B; Liu R; Liu W; Liu A; Zheng Q; Zhang Y
Cancer Cell Int; 2023 Nov; 23(1):281. PubMed ID: 37981695
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.
Makita S; Imaizumi K; Kurosawa S; Tobinai K
Drugs Context; 2019; 8():212567. PubMed ID: 30815024
[TBL] [Abstract][Full Text] [Related]
19. CAR T-cell therapy for relapsed/refractory non-Hodgkin's lymphoma: a comprehensive review.
St-Pierre F; Gordon LI
Clin Adv Hematol Oncol; 2022 May; 20(5):309-318. PubMed ID: 35579590
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]